Expertise in
3
conditions

Dr. Roel Querubin

Rheumatology
Marietta Rheumatology Associates PC
670 North Ave NW Ste 100, 
Marietta, GA 
Offers Telehealth
Expertise in
3
conditions
Marietta Rheumatology Associates PC
670 North Ave NW Ste 100, 
Marietta, GA 

Overview

Roel Querubin is a Rheumatologist in Marietta, Georgia. Dr. Querubin is highly rated in 3 conditions, according to our data. His top areas of expertise are Fibromyalgia, Rheumatoid Arthritis (RA), Axial Spondyloarthritis (AxSpA), and Psoriatic Arthritis.

His clinical research consists of participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Rheumatology

Licenses

Internal Medicine in GA

Hospital Affiliations

Wellstar Paulding Medical Center
Wellstar Cobb Medical Center
Wellstar Kennestone Regional Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
SelectHealth
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

Marietta Rheumatology Associates PC
670 North Ave NW Ste 100, Marietta, GA 30060
Other Locations
Office
670 North Ave NW Ste 300, Marietta, GA 30060

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 20, 2025
Intervention Type: Drug
Study Drug: LY3361237
Study Phase: Phase 2
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
Enrollment Status: Terminated
Publish Date: April 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: November 19, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 8 Less Clinical Trials
Similar Doctors
Arezou Khosroshahi
Expertise in
13
conditions
Dr. Arezou Khosroshahi
Rheumatology
Expertise in
13
conditions
Dr. Arezou Khosroshahi
Rheumatology

Emory Clinic At 1365 Clifton Road

1365 Clifton Road Northeast, BldgA, 
Atlanta, GA 
 (15.4 miles away)
404-778-4366
Experience:
25+ years
Languages Spoken:
English, Farsi
See accepted insurances
Offers Telehealth

Arezou Khosroshahi is a Rheumatologist in Atlanta, Georgia. Dr. Khosroshahi has been practicing medicine for over 25 years is highly rated in 13 conditions, according to our data. Her top areas of expertise are IgG4-Related Disease, Lupus Nephritis, MAGIC Syndrome, and Light Chain Deposition Disease (LCDD).

Expertise in
41
conditions
Dr. Mohammad Kamran
Rheumatology
Expertise in
41
conditions
Dr. Mohammad Kamran
Rheumatology

Wellstar Medical Group LLC

3747 Roswell Rd, 
Marietta, GA 
 (6.7 miles away)
Languages Spoken:
English, Farsi
See accepted insurances
Accepting New Patients
Offers Telehealth

Mohammad Kamran is a Rheumatologist in Marietta, Georgia. Dr. Kamran is highly rated in 41 conditions, according to our data. His top areas of expertise are Rheumatoid Arthritis (RA), Psoriatic Arthritis, Dermatomyositis, and Gout. Dr. Kamran is currently accepting new patients.

Expertise in
6
conditions
Dr. Jorg Goronzy
Rheumatology
Expertise in
6
conditions
Dr. Jorg Goronzy
Rheumatology

Emory Clinic Endcrnlgy/Rheumtlg

1365 Clifton Rd NE, 
Atlanta, GA 
 (15.7 miles away)
404-778-4366
Languages Spoken:
English
See accepted insurances

Jorg Goronzy is a Rheumatologist in Atlanta, Georgia. Dr. Goronzy is highly rated in 6 conditions, according to our data. His top areas of expertise are Temporal Arteritis, Giant Cell Arteritis (GCA), Vasculitis, and Juvenile Temporal Arteritis.

Frequently Asked Questions about Dr. Roel Querubin

How do I make an appointment with Dr. Roel Querubin?

You can book an appointment with Dr. Roel Querubin by calling their office at 770-590-8328. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Roel Querubin a top-rated expert for Fibromyalgia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Roel Querubin is classified as an Advanced expert for Fibromyalgia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Roel Querubin specialize in?

While Dr. Roel Querubin is a Rheumatology, they have specific expertise in Fibromyalgia, Rheumatoid Arthritis (RA), and Axial Spondyloarthritis (AxSpA). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Roel Querubin accept my insurance?

Dr. Roel Querubin accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 770-590-8328 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Querubin's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile